Egypt
· Delayed Price · Currency is EGP EGX: RMDA Statistics
Total Valuation
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has a market cap or net worth of EGP 5.58 billion. The enterprise value is 6.44 billion.
| Market Cap | 5.58B |
| Enterprise Value | 6.44B |
Important Dates
The next estimated earnings date is Thursday, February 27, 2025.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has 1.50 billion shares outstanding. The number of shares has increased by 0.76% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.50B |
| Shares Change (YoY) | +0.76% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 2.90% |
| Owned by Institutions (%) | 11.48% |
| Float | 850.16M |
Valuation Ratios
The trailing PE ratio is 20.95 and the forward PE ratio is 12.05.
| PE Ratio | 20.95 |
| Forward PE | 12.05 |
| PS Ratio | 2.39 |
| PB Ratio | 2.96 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | 614.81 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.35, with an EV/FCF ratio of 709.56.
| EV / Earnings | 24.20 |
| EV / Sales | 2.78 |
| EV / EBITDA | 10.35 |
| EV / EBIT | 11.83 |
| EV / FCF | 709.56 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.60.
| Current Ratio | 1.52 |
| Quick Ratio | 0.57 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 1.85 |
| Debt / FCF | 126.51 |
| Interest Coverage | 2.08 |
Financial Efficiency
Return on equity (ROE) is 16.57% and return on invested capital (ROIC) is 11.49%.
| Return on Equity (ROE) | 16.57% |
| Return on Assets (ROA) | 9.92% |
| Return on Capital (ROIC) | 11.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +95.19% in the last 52 weeks. The beta is 0.30, so Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +95.19% |
| 50-Day Moving Average | 3.41 |
| 200-Day Moving Average | 2.81 |
| Relative Strength Index (RSI) | 66.11 |
| Average Volume (20 Days) | 9,135,862 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. had revenue of EGP 2.32 billion and earned 266.06 million in profits. Earnings per share was 0.18.
| Revenue | 2.32B |
| Gross Profit | 1.07B |
| Operating Income | 544.33M |
| Pretax Income | 390.40M |
| Net Income | 266.06M |
| EBITDA | 617.72M |
| EBIT | 544.33M |
| Earnings Per Share (EPS) | 0.18 |
Balance Sheet
The company has 310.60 million in cash and 1.15 billion in debt, giving a net cash position of -837.11 million or -0.56 per share.
| Cash & Cash Equivalents | 310.60M |
| Total Debt | 1.15B |
| Net Cash | -837.11M |
| Net Cash Per Share | -0.56 |
| Equity (Book Value) | 1.91B |
| Book Value Per Share | 1.25 |
| Working Capital | 836.72M |
Cash Flow
In the last 12 months, operating cash flow was 65.64 million and capital expenditures -56.57 million, giving a free cash flow of 9.07 million.
| Operating Cash Flow | 65.64M |
| Capital Expenditures | -56.57M |
| Free Cash Flow | 9.07M |
| FCF Per Share | 0.01 |
Margins
Gross margin is 46.04%, with operating and profit margins of 23.48% and 12.40%.
| Gross Margin | 46.04% |
| Operating Margin | 23.48% |
| Pretax Margin | 16.84% |
| Profit Margin | 12.40% |
| EBITDA Margin | 26.64% |
| EBIT Margin | 23.48% |
| FCF Margin | 0.39% |
Dividends & Yields
This stock pays an annual dividend of 0.07, which amounts to a dividend yield of 1.84%.
| Dividend Per Share | 0.07 |
| Dividend Yield | 1.84% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | 17.84% |
| Buyback Yield | -0.76% |
| Shareholder Yield | 1.07% |
| Earnings Yield | 4.77% |
| FCF Yield | 0.16% |
Stock Splits
The last stock split was on September 21, 2023. It was a forward split with a ratio of 1.52253.
| Last Split Date | Sep 21, 2023 |
| Split Type | Forward |
| Split Ratio | 1.52253 |
Scores
Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. has an Altman Z-Score of 3.03.
| Altman Z-Score | 3.03 |
| Piotroski F-Score | n/a |